CYP2A6 genotype, phenotype, and the use of nicotine metabolites as biomarkers during ad libitum smoking.
- Authors
- Malaiyandi, Viba; Goodz, Shari D; Sellers, Edward M; Tyndale, Rachel F
- Year
- 2006
- Journal
- Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
- PMID
- 17035386
- DOI
- 10.1158/1055-9965.EPI-05-0723
CYP2A6 inactivates nicotine to cotinine and cotinine to 3-hydroxycotinine. We investigated which of plasma nicotine and metabolites were most related to CYP2A6 genotype and smoking levels. We assessed demographic and smoking histories in 152 Caucasian ad libitum smokers, measured breath carbon monoxide (CO) levels, and determined plasma nicotine, cotinine, and 3-hydroxycotinine by high-performance liquid chromatography and CYP2A6 genotypes by PCR. Cigarettes per day was most closely related to CO (r = 0.60, P < 0.001) followed by plasma cotinine (r = 0.53, P < 0.001), whereas plasma cotinine was most strongly correlated with CO levels (r = 0.74, P < 0.001), confirming that cotinine is a good indicator of smoking levels; this was not limited by CYP2A6 variants. 3-Hydroxycotinine/cotinine is reported to be a good marker of CYP2A6 activity, and we found that the 3-hydroxycotinine/(cotinine + nicotine) ratio was most correlated with CYP2A6 genotype (r = 0.38, P < 0.001). Inclusion of the CYP2A6*12A allele strengthened the correlation (r = 0.46, P < 0.001), suggesting that the identification of novel alleles will continue to improve this relationship. Nicotine metabolism is slower in smokers, and we have shown that CYP2A6 is reduced by nicotine treatment in monkeys. Here, we found that plasma nicotine levels were inversely correlated with CYP2A6 activity (3-hydroxycotinine/cotinine, r = -0.41, P < 0.001) among those without CYP2A6 variants, suggesting a reduction in metabolism with higher nicotine levels. Together, these findings (a) confirm the use of plasma cotinine and CO as indicators of Caucasians' smoking levels, and that this is not limited by CYP2A6 genetic variation; (b) indicate that 3-hydroxycotinine/cotinine and 3-hydroxycotinine/(cotinine + nicotine) are moderately good indicators of the CYP2A6 genotype; and (c) support that nicotine exposure may reduce its own metabolism.
No figures extracted from this document.
No chunks β full text not yet ingested.
No entities extracted from this document yet.
No uploaded files.
No citations found.
In this knowledge base
External
| Title | Authors | Journal | Year | Link |
|---|---|---|---|---|
| Variation in Nicotine Metabolization According to Biological Factors and Type of Nicotine Consumer. | PΓ©rez-MartΓn H et al. | β | 2023 | β |
| Changes in the salivary cotinine cut-offs to discriminate smokers and non-smokers before and after Spanish smoke-free legislation. | PΓ©rez-MartΓn H et al. | β | 2022 | β |
| Ethnic differences in excretion of butadiene-DNA adducts by current smokers. | Jokipii Krueger CC et al. | β | 2021 | β |
| Effects of Genetic Polymorphisms of Drug Transporter ABCB1 (MDR1) and Cytochrome P450 Enzymes CYP2A6, CYP2B6 on Nicotine Addiction and Smoking Cessation. | Muderrisoglu A et al. | β | 2020 | β |
| Relationships between the Nicotine Metabolite Ratio and a Panel of Exposure and Effect Biomarkers: Findings from Two Studies of U.S. Commercial Cigarette Smokers. | Carroll DM et al. | β | 2020 | β |
| The relationship between nicotine metabolism and nicotine and carcinogen exposure among American Indian commercial cigarette smokers and electronic nicotine delivery system users. | Carroll DM et al. | β | 2019 | β |
| Understanding the implications of the biobehavioral basis of nicotine addiction and its impact on the efficacy of treatment. | Bozinoff N et al. | β | 2018 | β |
| Distribution of polymorphic variants of CYP2A6 and their involvement in nicotine addiction. | LΓ³pez-Flores LA et al. | β | 2017 | β |
| Application of a pharmacokinetic/pharmacogenetic approach to assess the nicotine metabolic profile of smokers in the real-life setting. | Fogli S et al. | β | 2016 | β |
| Genetic Relationship between Schizophrenia and Nicotine Dependence. | Chen J et al. | β | 2016 | β |
| Genome-Wide Meta-Analysis of Cotinine Levels in Cigarette Smokers Identifies Locus at 4q13.2. | Ware JJ et al. | β | 2016 | β |
| Nicotine Dependence and Urinary Nicotine, Cotinine and Hydroxycotinine Levels in Daily Smokers. | Van Overmeire IP et al. | β | 2016 | β |
| Nicotine Metabolism in Young Adult Daily Menthol and Nonmenthol Smokers. | Fagan P et al. | β | 2016 | β |
| Biomarkers of Response to Smoking Cessation Pharmacotherapies: Progress to Date. | Mamoun M et al. | β | 2015 | β |
| Biomarkers of tobacco smoke exposure in racial/ethnic groups at high risk for lung cancer. | Fagan P et al. | β | 2015 | β |
| N-acetyltransferase 1 polymorphism increases cotinine levels in Caucasian children exposed to secondhand smoke: the CCAAPS birth cohort. | LeMasters GK et al. | β | 2015 | β |
| Nicotine metabolite ratio (3-hydroxycotinine/cotinine) in plasma and urine by different analytical methods and laboratories: implications for clinical implementation. | Tanner JA et al. | β | 2015 | β |
| Pharmacogenetics of nicotine and associated smoking behaviors. | Tanner JA et al. | β | 2015 | β |
| 1,3-Butadiene exposure and metabolism among Japanese American, Native Hawaiian, and White smokers. | Park SL et al. | β | 2014 | β |
| Nicotine dependence as a moderator of genetic influences on smoking cessation treatment outcome. | Leventhal AM et al. | β | 2014 | β |
| Validation of a LC-MS/MS method for quantifying urinary nicotine, six nicotine metabolites and the minor tobacco alkaloids--anatabine and anabasine--in smokers' urine. | McGuffey JE et al. | β | 2014 | β |
| Variants in two adjacent genes, EGLN2 and CYP2A6, influence smoking behavior related to disease risk via different mechanisms. | Bloom AJ et al. | β | 2014 | β |
| Comparisons of CYP2A6 genotype and enzyme activity between Swedes and Koreans. | Djordjevic N et al. | β | 2013 | β |
| Nicotine metabolism and addiction among adolescent smokers. | Rubinstein ML et al. | β | 2013 | β |
| The contribution of common UGT2B10 and CYP2A6 alleles to variation in nicotine glucuronidation among European Americans. | Bloom AJ et al. | β | 2013 | β |
| Cotinine: Beyond that Expected, More than a Biomarker of Tobacco Consumption. | Moran VE | β | 2012 | β |
| Gender-stratified gene and gene-treatment interactions in smoking cessation. | Lee W et al. | β | 2012 | β |
| PharmGKB summary: very important pharmacogene information for cytochrome P-450, family 2, subfamily A, polypeptide 6. | McDonagh EM et al. | β | 2012 | β |
| Associations of CYP2A6 genotype with smoking behaviors in southern China. | Liu T et al. | β | 2011 | β |
| Biomarkers to optimize the treatment of nicotine dependence. | Schnoll RA et al. | β | 2011 | β |
| Genetic vulnerability and susceptibility to substance dependence. | Bierut LJ | β | 2011 | β |
| Systematic review of the relationship between the 3-hydroxycotinine/cotinine ratio and cigarette dependence. | West O et al. | β | 2011 | β |
| The contribution of common CYP2A6 alleles to variation in nicotine metabolism among European-Americans. | Bloom J et al. | β | 2011 | β |
| Enzyme-linked immunosorbent assay of nicotine metabolites. | Matsumoto A et al. | β | 2010 | β |
| [Light and intermittent tobacco smokers]. | Underner M et al. | β | 2010 | β |
| Liu wei di huang wan, a well-known traditional Chinese medicine, induces CYP1A2 while suppressing CYP2A6 and N-acetyltransferase 2 activities in man. | Chen Y et al. | β | 2010 | β |
| Plant polyphenol curcumin significantly affects CYP1A2 and CYP2A6 activity in healthy, male Chinese volunteers. | Chen Y et al. | β | 2010 | β |
| The Role of Genetics in Nicotine Dependence: Mapping the Pathways from Genome to Syndrome. | Mackillop J et al. | β | 2010 | β |
| Association of nicotine metabolite ratio and CYP2A6 genotype with smoking cessation treatment in African-American light smokers. | Ho MK et al. | β | 2009 | β |
| Genetic and environmental influences on the ratio of 3'hydroxycotinine to cotinine in plasma and urine. | Swan GE et al. | β | 2009 | β |
| Nicotine dependence pharmacogenetics: role of genetic variation in nicotine-metabolizing enzymes. | Ray R et al. | β | 2009 | β |
| Reconciling human smoking behavior and machine smoking patterns: implications for understanding smoking behavior and the impact on laboratory studies. | Marian C et al. | β | 2009 | β |
| Tobacco addiction and pharmacogenetics of nicotine metabolism. | Swan GE et al. | β | 2009 | β |
| Utility and relationships of biomarkers of smoking in African-American light smokers. | Ho MK et al. | β | 2009 | β |
| A novel CYP2A6 allele, CYP2A6*23, impairs enzyme function in vitro and in vivo and decreases smoking in a population of Black-African descent. | Ho MK et al. | β | 2008 | β |
| Stability of the nicotine metabolite ratio in ad libitum and reducing smokers. | Mooney ME et al. | β | 2008 | β |
| Estimation of urinary cotinine cut-off points distinguishing non-smokers, passive and active smokers. | ZieliΕska-Danch W et al. | β | 2007 | β |
| Genetic variability in CYP2A6 and the pharmacokinetics of nicotine. | Mwenifumbo JC et al. | β | 2007 | β |